Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder

Abstract: Background: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. In real-world settings, OLZ/SAM treatment may be associated with healthcare resource utilization (HCRU) reductions. This study examined the impact of initiating treatment with OLZ/SAM on HCRU among patients with schizophrenia (SZ) or bipolar I disorder (BD-I). Methods: This retrospective analysis utilized administrative claims data from April 19, 2021, to December 31, 2022, from Komodo Healthcare Map. Adults with SZ or BD-I with continuous enrollment ≥6 months before (baseline) and after (follow-up) OLZ/SAM initiation were eligible. Inpatient (IP) admissions, lengths of stay (LOS), and emergency department (ED) and outpatient (OP) visits were compared between the 6-month baseline and follow-up periods. Results: Patients (SZ: n=855; BD-I: n=691) had a mean age of ~40 years (female: SZ=47%; BD-I=69%). Proportions of patients with all-cause IP admissions and ED visits significantly decreased (IP: P 0.001; ED: P 0.05) in both cohorts, as did those with mental health–related IP admissions (P 0.001) and ED visits (P 0.001), between baseline and follow-up. Mean IP LOS decreased in both cohorts, reaching statistical significance among BD-I patients for all-cause (P=0.011) and mental health–related (P=0.007) HCRU. Proportions of patients with OP visits were similar in both cohorts. Conclusions: Among patients with SZ or BD-I, real-world OLZ/SAM initiation was associated with significant reductions in proportions of patients with all-cause and mental health–related hospitalizations and ED visits, potentially resulting in clinically meaningful reductions in disease burden, as evidenced by changes in hospital-based care.Short Description: This study examined the real-world impact of initiating treatment with a combination of olanzapine and samidorphan (OLZ/SAM) on healthcare resource utilization among patients with schizophrenia or bipolar I disorder. In both cohorts, initiating OLZ/SAM was associated with significant reductions in proportions of patients with all-cause and mental health–related hospitalizations and emergency department visits. The observed reductions in hospital-based care suggest that treatment with OLZ/SAM may result in clinically meaningful reductions in disease burden.Name of Sponsoring Organization(s): Alkermes, Inc.